Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

174.43B

Market cap174.43B

Price-Earnings ratio

-51.15

Price-Earnings ratio-51.15

Dividend yield

2.37%

Dividend yield2.37%

Average volume

7.77M

Average volume7.77M

High today

$137.12

High today$137.12

Low today

$133.30

Low today$133.30

Open price

$133.99

Open price$133.99

Volume

5.68M

Volume5.68M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $136.81. The company's market cap stands at 174.43B, with a P/E ratio of -51.15 and a dividend yield of 2.37%.

As of 2026-08-12, Gilead Sciences(GILD) stock has fluctuated between $133.30 and $137.12. The current price stands at $136.81, placing the stock +2.6% above today's low and -0.2% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 5.68M, against a daily average of 7.77M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 7h

Gilead Sciences Starts AI Biomarker Research Partnership For Oncology

Gilead Sciences (NasdaqGS:GILD) announced a new AI powered translational research collaboration with Nucleai focused on biomarker discovery and precision oncolo...

TipRanks 2d

Lakefront Biotherapeutics Boosts Immunology Push With Ouro Deal and Strong Cash Outlook

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 5d

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target

Michael Okunewitch, an analyst from Maxim Group, reiterated the Buy rating on Gilead Sciences. The associated price target remains the same with $165.00. Unloc...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More GILD News

Simply Wall St 6d

Gilead Sciences Could Be Trading At A 20% Discount Following Raised Guidance

Gilead Sciences (GILD) is back in focus after reporting its strongest base business growth in three years, raising full year guidance for HIV sales and core ope...

Nasdaq 6d

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.